{
 "as_of": "2026-11-06",
 "cmr": "se-cm-kg/SSME/SE0009723125",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# NextCell Pharma AB (First North Sweden: SE0009723125) — research page\n\nAs of 2026-11-06 · se-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is NextCell Pharma AB, listed on First North Sweden under ticker SE0009723125, with ISIN SE0009723125 and LEI 549300PBFGB5JYKXGA45. Security type, segment, sector and jurisdiction are not on the record. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 46 filings across 22 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 9 days. The latest filing is dated 2026-10-26, eleven days before the record date of 2026-11-06, and is a Company Announcement. The exchange median cadence gap is 11.0 days, with a median of 21 filings and a median latency of 7 days, across 325 issuers on First North Sweden. Sector peer figures are not on the record for this market.\n\n## Auditor\n\nThe auditor and its location are not on the record. Auditor changes are not on the record, as the lifecycle type map for this register is not yet in place.\n\n## Events and halts\n\nListing, delisting, name change, domicile change and segment move are not on the record, as the lifecycle type map for this register is not yet in place. The issuer is not halted.\n\n## Orderability\n\nThe outcome is not determinable under rule version acm-68000/se/mifid-ii-product-governance/r1, as the chapter as of 2026-11-04 carries no client categories. No client category is named.\n\n## Coverage\n\nNo research houses were found on the issuer's investor-relations pages read.\n\n## Open research\n\nOne openly published research note is on the record, from Redeye dated 2025-07-25.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe vintage is not sealed for this market. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record start date is not on the record.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.se-cm-kg.ai/events/SSME/SE0009723125 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)\n- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://res.cloudinary.com/redeye/image/upload/v1753424263/article-pdfs/update/nextcell-pharma-q3-2024-2025-largely-as-expected_vcmp43.pdf (open research)\n- https://mcp.se-cm-kg.ai/record/SSME/SE0009723125 (the record)\n",
 "market": "SE",
 "node": "se-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the SE vintage is not sealed; the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "SE",
    "state": "not_on_record"
   },
   "changes": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "se-cm-kg/SSME/SE0009723125",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 325,
     "median_cadence_gap_days": 11,
     "median_filings": 21,
     "median_latency_days": 7,
     "name": "First North Sweden"
    },
    "sector": {
     "market": "SE",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Annual financial report": 2,
    "Changes in board/management/certified adviser/auditor/liquidity provider": 2,
    "Company Announcement": 6,
    "Decisions of general meeting": 3,
    "Interim report (Q1 and Q3)": 6,
    "Investor News": 24,
    "Notice to general meeting": 3
   },
   "cadence_median_gap_days": 9,
   "filing_days": 22,
   "filings": 46,
   "latency_days": 11,
   "latest": [
    {
     "category": "Company Announcement",
     "date": "2026-10-26",
     "source": "https://view.news.eu.nasdaq.com/view?id=bf5b73356502b93a3e650ae843f2f2b5a&lang=sv&src=listed",
     "title": "NextCell rapporterar numeriskt gynnsamma resultat hos yngre barn - vuxenstrategin ligger fast",
     "type": "Company Announcement"
    },
    {
     "category": "Company Announcement",
     "date": "2026-10-26",
     "source": "https://view.news.eu.nasdaq.com/view?id=b7d0bc7eddea9ab780a270cedb1d43bce&lang=en&src=listed",
     "title": "NextCell reports encouraging numerical results in younger children - strategy for adults remains unchanged",
     "type": "Company Announcement"
    },
    {
     "category": "Investor News",
     "date": "2026-10-19",
     "source": "https://view.news.eu.nasdaq.com/view?id=ba5ec2ef450365f6bb0f526507c111f25&lang=en&src=listed",
     "title": "NextCell provides update on timing of ProTrans-Young results",
     "type": "Investor News"
    },
    {
     "category": "Investor News",
     "date": "2026-10-19",
     "source": "https://view.news.eu.nasdaq.com/view?id=b0035e34242ac8c3034b2cb6f413aa259&lang=sv&src=listed",
     "title": "NextCell uppdaterar om tidplanen för resultat från ProTrans-Young",
     "type": "Investor News"
    },
    {
     "category": "Investor News",
     "date": "2026-09-28",
     "source": "https://view.news.eu.nasdaq.com/view?id=b8b4a1fd1211cb4858869776889462749&lang=en&src=listed",
     "title": "NextCell to present at the INNODIA Symposium during EASD 2026",
     "type": "Investor News"
    }
   ],
   "latest_filing_date": "2026-10-26",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.se-cm-kg.ai/events/SSME/SE0009723125",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "First North Sweden"
   },
   "isin": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0009723125"
   },
   "jurisdiction": {
    "market": "SE",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-09",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN SE0009723125)",
    "state": "sourced",
    "value": "549300PBFGB5JYKXGA45"
   },
   "name": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "NextCell Pharma AB"
   },
   "sector": {
    "market": "SE",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "SE",
    "state": "not_on_record"
   },
   "segment": {
    "market": "SE",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0009723125"
   },
   "website": {
    "market": "SE",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "SE",
  "node": "se-cm-kg",
  "numbers_hash": "sha256:4005032212400601e5259d8d1e619d11ae0a636ec009d9b8a42eab98e4f71d59",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [
    {
     "date": "2025-07-25",
     "kind": "independent",
     "publisher": "Redeye",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-12",
     "source": "https://res.cloudinary.com/redeye/image/upload/v1753424263/article-pdfs/update/nextcell-pharma-q3-2024-2025-largely-as-expected_vcmp43.pdf",
     "state": "sourced",
     "title": "NextCell Pharma Q3 2024/2025: Largely as expected"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://se.eu-cm-kg.ai/book/aio.json",
    "door": "https://se.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/se/mifid-ii-product-governance/r1",
   "section": "se.aio.v5"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.se-cm-kg.ai/record/SSME/SE0009723125",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-09",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:4005032212400601e5259d8d1e619d11ae0a636ec009d9b8a42eab98e4f71d59",
 "path": "/se/SSME/SE0009723125",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is NextCell Pharma AB, listed on First North Sweden under ticker SE0009723125, with ISIN SE0009723125 and LEI 549300PBFGB5JYKXGA45. Security type, segment, sector and jurisdiction are not on the record. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 46 filings across 22 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 9 days. The latest filing is dated 2026-10-26, eleven days before the record date of 2026-11-06, and is a Company Announcement. The exchange median cadence gap is 11.0 days, with a median of 21 filings and a median latency of 7 days, across 325 issuers on First North Sweden. Sector peer figures are not on the record for this market.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor and its location are not on the record. Auditor changes are not on the record, as the lifecycle type map for this register is not yet in place.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "Listing, delisting, name change, domicile change and segment move are not on the record, as the lifecycle type map for this register is not yet in place. The issuer is not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable under rule version acm-68000/se/mifid-ii-product-governance/r1, as the chapter as of 2026-11-04 carries no client categories. No client category is named.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the issuer's investor-relations pages read.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "One openly published research note is on the record, from Redeye dated 2025-07-25.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The vintage is not sealed for this market. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record start date is not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.se-cm-kg.ai/events/SSME/SE0009723125"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation"
  },
  {
   "for": "the orderability chapter",
   "source": "https://se.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "open research",
   "source": "https://res.cloudinary.com/redeye/image/upload/v1753424263/article-pdfs/update/nextcell-pharma-q3-2024-2025-largely-as-expected_vcmp43.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.se-cm-kg.ai/record/SSME/SE0009723125"
  }
 ],
 "title": "NextCell Pharma AB (SE0009723125) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}